作者
Luis Ortega-Paz, Wilbert Bor, Francesco Franchi, Wout WA van de Broek, Fabiana Rollini, Salvatore Giordano, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Haroutioun Garabedian, Tala Al Saleh, Ekin Uzunoglu, Xuan Zhou, Andrea Rivas, Andres M Pineda, Siva Suryadevara, Daniel Soffer, Madeline K Mahowald, Calvin Y Choi, Martin M Zenni, Fladia Phoenix, Ramzi A Ajjan, Jurrien M Ten Berg, Dominick J Angiolillo
发表日期
2024/4/7
期刊
JACC: Cardiovascular Interventions
出版商
Elsevier
简介
Background
Among patients treated with a novel oral anticoagulant (NOAC) undergoing percutaneous coronary intervention (PCI), combination therapy with clopidogrel (i.e., known as dual antithrombotic therapy [DAT]) is the treatment of choice. However, there are concerns for individuals with impaired response to clopidogrel.
Objectives
To assess the pharmacodynamic (PD) effects of clopidogrel vs. low-dose ticagrelor in patients with impaired clopidogrel response assessed by the ABCD‐GENE score.
Methods
This was a prospective, randomized PD study of NOAC-treated patients undergoing PCI. Patients with an ABCD‐GENE score ≥10 (n=39), defined as having impaired clopidogrel response, were randomized to low-dose ticagrelor (n=20; 60 mg/bid) or clopidogrel (n=19; 75 mg/qd). Patients with an ABCD-GENE<10 (n=42) were treated with clopidogrel (75 mg/qd; control cohort). PD assessments at baseline …
学术搜索中的文章
L Ortega-Paz, W Bor, F Franchi, WWA van de Broek… - JACC: Cardiovascular Interventions, 2024